Medtronic Plc MDT has seen robust
financial performance over the past year, with its stock experiencing a 15% rise.
Analysts are bullish on the company, with positive expectations for its upcoming
earnings estimates. An interesting development is the company's spin-off of its
Diabetes business, which is anticipated to overcome stagnation and inject growth into the company.
Jim Cramer supports Medtronic, naming it a 'Medical Device Powerhouse', which solidifies the company's strong position in the
Healthcare sector. Despite a few dips in the stock market, Medtronic has demonstrated a unique fit for
Halal Portfolios and has been labelled as one of the best high-yield dividend stocks for 2025. There is significant excitement surrounding the company's upcoming
financial results for its fiscal year 2026. A notable turning point was when the company scored an impressive daily turnover of $595.29 Million.
Institutional shareholders play a significant role, controlling around 87% of the company. Finally, the company plans on
increasing its dividend.
Medtronic Plc MDT News Analytics from Wed, 20 Nov 2024 08:00:00 GMT to Fri, 08 Aug 2025 22:00:25 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
